Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 
Home > News > ASCO 2014

ASCO 2014 

01.06.2014 

ASCO 2014: IBCSG plenary session on TEXT & SOFT trial results.

The Aromatase Inhibitor (AI) Question

This landmark study is the first to demonstrate that taking exemestane along with blocking ovarian function prevents cancer recurrence in young women with hormone‐sensitive breast cancer, a common type of breast cancer. These practice‐changing results provide a new treatment option for young women with hormone‐sensitive breast cancer, previously only recommended for postmenopausal women. This IBCSG study is the culmination of a successful, decade‐long worldwide collaboration spanning 27 countries and 6 continents.

Press Release
Please contact press@ibcsg.org for media inquiries.

ASCO 2014 Plenary Presentation
Dr. Olivia Pagani presented on behalf of IBCSG at the June 1 plenary session.

New England Journal of Medicine
We are pleased to publish our results in the July 10 print issue of The New England Journal of Medicine.

  • Click to access the paper. Full content is available by paid subscription.

ASCO 2014 Related Abstracts
We also presented the following related TEXT and SOFT abstracts:

Women who participated in the TEXT and SOFT clinical trials should contact their treating physician for additional information.

 

 

News

09.09.2018:
9.9.2018 - RACE FOR LIFE, Bundesplatz Bern

19.06.2018:
PINK GOLFTOUR 2018  

10.06.2018:
32. SCHWEIZER FRAUENLAUF woman 4 woman - walking together, stronger than ever

All News

 
  Print